NFE2L2 and hepatocellular carcinoma: In some cancer cell lines, drug resistance has been described after treatment with sorafenib: it has been demonstrated that upregulation of Nrf2 and pRB can inhibit sorafenib-induced ferroptosis in hepatocellular carcinoma cell lines [50].